<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655822</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-444-001</org_study_id>
    <nct_id>NCT02655822</nct_id>
  </id_info>
  <brief_title>Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers</brief_title>
  <official_title>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corvus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Corvus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small
      molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune
      system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444
      as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various
      solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine
      suppresses the anti-tumor activity of T cells and other immune cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small
      molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune
      system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444
      as a single agent and in combination with atezolizumab, an intravenous PD-L1 inhibitor.
      CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the
      anti-tumor activity of T cells and other immune cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) of CPI-444 as a single agent and in combination with atezolizumab</measure>
    <time_frame>28 days following first administration of CPI-444</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate per RECIST v1.1 criteria of CPI-444 as a single agent and in combination with atezolizumab</measure>
    <time_frame>From start of treatment to end of treatment, up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of CPI-444 as a single agent and in combination with atezolizumab</measure>
    <time_frame>Continuously, up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean and median Area under the curve (AUC) of CPI-444</measure>
    <time_frame>Day 14 of Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean and median Maximum concentration (Cmax) of CPI-444</measure>
    <time_frame>Day 14 of Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">534</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Malignant Melanoma</condition>
  <condition>Renal Cell Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-444</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-444</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-444</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-444 + atezolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-444</intervention_name>
    <description>100 mg orally twice daily for the first 14 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-444</intervention_name>
    <description>100 mg orally twice daily for 28 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-444</intervention_name>
    <description>200 mg orally once daily for the first 14 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-444 + atezolizumab</intervention_name>
    <description>CPI-444 orally in combination with atezolizumab intravenously.</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

          2. Documented incurable cancer with one of the following histologies: non-small cell
             lung cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
             head and neck cancer, colorectal cancer with microsatellite instability (MSI), and
             bladder cancer.

          3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
             1.1).

          4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
             progressing disease.

        Exclusion Criteria

          1. History of severe hypersensitivity reaction to monoclonal antibodies.

          2. Any active autoimmune disease or a documented history of serious autoimmune disease
             within the past 5 years requiring immunosuppressive therapy.

          3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

          4. The use of any investigational medication or device in the 30 days prior to screening
             and throughout the study is prohibited.

          5. If a patient is currently receiving denosumab, this must be discontinued prior to
             enrollment. Substitution with biphosphonates are acceptable.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Fisher</last_name>
    <role>Study Director</role>
    <affiliation>Corvus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M Fisher</last_name>
    <email>inquiry@corvuspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley McClain</last_name>
      <phone>704-947-6599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 27, 2016</lastchanged_date>
  <firstreceived_date>January 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>MEL</keyword>
  <keyword>RCC</keyword>
  <keyword>TNBC</keyword>
  <keyword>Triple Negative Breast Neoplasms</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>CRC</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>Skin Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
